BioScience Laboratories Announces Testing Capabilities for NDM-1

Article

BioScience Laboratories has obtained seven clinical isolates of Carbapenem-Resistant (CR) Klebsiella pneumoniae and Escherichia coli. These organisms provide a strong model for predicting a product's efficacy against superbugs such as the New Delhi metallo-a-lactamase 1 (NDM-1) strain that has aroused recent worldwide concern. Carbapenems are historically used as a last resort for fighting bacterial infections, particularly versus multidrug-resistant Gram-negative species.

The five isolates of CR-Klebsiella pneumoniae and two isolates of CR-Escherichia coli are being used by BioScience Laboratories microbiologists to test products for their in-vitro efficacy as topical antimicrobials or hard-surface disinfectants to provide data predictive of a product's efficacy versus the New Delhi metallo-a-lactamase 1 (NDM-1) strain.

BioScience Laboratories, Inc. was founded in 1991 in Bozeman, Mont., to provide antimicrobial product testing and result interpretation grounded in science.

Related Videos
NFID Medical Director, Robert H. Hopkins, Jr., MD  (Photo courtesy by Evoke Kyne)
Shelley Summerlin-Long, MPH, MSW, BSN, RN, senior quality improvement leader, infection prevention, UNC Medical Center, Chapel Hill, North Carolina
Infection Control Today Infection Intel: Staying Ahead with Company updates and product Innovations.
An eye instrument holding an intraocular lens for cataract surgery. How to clean and sterilize it appropriately?   (Adobe Stock 417326809By Mohammed)
Christopher Reid, PhD  (Photo courtesy of Christopher Reid, PhD)
Paper with words antimicrobial resistance (AMR) and glasses.   (Adobe Stock 126570978 by Vitalii Vodolazskyi)
3D illustration: Candida auris   (Adobe Stock 635576411 By Niamh )
 MIS-C (Adobe Stock 350657530 by Bernard Chantal)
Set of white bottles with cleaning liquids on the white background. (Adobe Stock 6338071172112 by zolnierek)
Related Content